EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prospective Assessment of MR Guided Single-Fraction Stereotactic Ablative Radiation Therapy for Peripheral Lung Metastases: Dosimetric and Clinical Outcomes

Svenja Hering, Richard Gaus, Jan Hofmaier, Sina Mansoorian, Sebastian Marschner, Nina-Sophie Schmidt-Hegemann, Vanessa da Silva Mendes, Amanda Tufman, Niels Reinmuth, Guillaume Landry, Maximilian Niyazi, Claus Belka und 2 weitere

Practical Radiation Oncology · 2025

DOI: 10.1016/j.prro.2025.05.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Practical Radiation Oncology, 2025. Verfasst von Svenja Hering und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany. Electronic address: Svenja.hering@tum.de. Hauptthemen laut MEDLINE: Lung Neoplasms, Radiosurgery, Radiotherapy, Image-Guided, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Aid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to evaluate the feasibility and safety of online MR guided single-fraction stereotactic ablative radiation therapy (SABR) and to assess acute changes in pulmonary function tests (PFTs), inflammatory markers, patient-reported quality of life (QoL), and dosimetric outcomes. METHODS AND MATERIALS: Patients with lung metastases were included in this single-center prospective study. Patients underwent MR guided single-fraction SABR. The primary endpoints encompassed local control (LC) and overall survival. Secondary endpoints included acute toxicity (Common Terminology Criteria for Adverse Events version 5.0), changes in PFTs, inflammatory markers, QoL, and dosimetric outcomes. RESULTS: Between 10/2020 and 10/2022, 26 patients with 30 lung metastases were prospectively enrolled. At a median follow-up of 19.9 months (range, 16.1 to 25.6 months), the 1- and 2-year LC rates were 96.2% (95% CI, 88.7% to 100.0%) and 77.5% (95% CI, 55.9% to 99.1%). No Common Terminology Criteria for Adverse Events grade 3+ side effects were observed. While there was a slight median reduction of 4% in forced expiratory volume in 1 second (L) (P = .009, range, -24% to 20%), other PFT parameters remained stable. The neutrophil-to-lymphocyte ratio increased by a median of 13% (P = .002, range, -10% to 207%), while serum C-reactive protein and albumin levels remained unchanged. Patient-reported QoL did not exhibit significant changes, except for a minimal increase in the median score for cognitive functioning from 1 to 1.5 (P = .041). CONCLUSIONS: MR guided single-fraction SABR is a safe and effective treatment option for peripheral lung metastases, demonstrating encouraging LC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsRadiosurgeryRadiotherapy, Image-GuidedMagnetic Resonance ImagingHumansMaleFemaleProspective StudiesMiddle AgedAgedQuality of LifeAged, 80 and overAdultTreatment Outcome

Autor:innen und Institutionen

  • Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany. Electronic address: Svenja.hering@tum.de.
  • Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany; TUM School of Computation, Information and Technology, Munich, Germany.
  • Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Pneumology, LMU University Hospital, LMU Munich, Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Asklepios Lung Clinic Munich-Gauting, Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany; Department of Radiation Oncology, University of Tübingen, Tübingen, Germany.

Förderung

  • German Cancer Aid

Zitieren

APA

Hering, S., Gaus, R., Hofmaier, J., Mansoorian, S., Marschner, S., Schmidt-Hegemann, N. S., Mendes, V. D. S., Tufman, A., Reinmuth, N., Landry, G., Niyazi, M., Belka, C., Corradini, S., & Eze, C. (2025). Prospective Assessment of MR Guided Single-Fraction Stereotactic Ablative Radiation Therapy for Peripheral Lung Metastases: Dosimetric and Clinical Outcomes. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2025.05.006

Vancouver

Hering S, Gaus R, Hofmaier J, Mansoorian S, Marschner S, Schmidt-Hegemann NS, et al. Prospective Assessment of MR Guided Single-Fraction Stereotactic Ablative Radiation Therapy for Peripheral Lung Metastases: Dosimetric and Clinical Outcomes. Practical Radiation Oncology. 2025. doi:10.1016/j.prro.2025.05.006

BibTeX
@article{Hering2025,
  author = {Hering, Svenja and Gaus, Richard and Hofmaier, Jan and Mansoorian, Sina and Marschner, Sebastian and Schmidt-Hegemann, Nina-Sophie and Mendes, Vanessa da Silva and Tufman, Amanda and Reinmuth, Niels and Landry, Guillaume and Niyazi, Maximilian and Belka, Claus and Corradini, Stefanie and Eze, Chukwuka},
  title = {Prospective Assessment of MR Guided Single-Fraction Stereotactic Ablative Radiation Therapy for Peripheral Lung Metastases: Dosimetric and Clinical Outcomes},
  journal = {Practical Radiation Oncology},
  year = {2025},
  doi = {10.1016/j.prro.2025.05.006}
}
Kostenlos starten →